PTO Form 1581 (Rev 9/2005) |
OMB No. 0651-0054 (Exp. 10/31/2017) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
85442528 |
LAW OFFICE ASSIGNED |
LAW OFFICE 116 |
MARK SECTION |
MARK |
CERULEAN |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
CERULEAN |
OWNER SECTION |
NAME |
Cerulean Pharma Inc. |
STREET |
840 Memorial Drive, 5th Floor |
CITY |
Cambridge |
STATE |
Massachusetts |
ZIP/POSTAL CODE |
02139 |
COUNTRY |
United States |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
pharmaceutical preparations for use in the diagnosis, prognosis or prevention of oncological diseases or disorders, including malignant cancers
or neoplasms; pharmaceutical preparations for use in the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including pre-cancerous diseases or disorders and benign
cancers or neoplasms, inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders; pharmaceutical preparations for use in modulating angiogenesis; pharmaceutical
preparations for use in the diagnosis, prognosis and prevention of oncological diseases or disorders, including malignant cancers or neoplasms, all containing nanometer size compounds which
facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including
pre-cancerous diseases or disorders and benign cancers or neoplasms, inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders, all containing nanometer size
compounds which facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in modulating angiogenesis, containing nanometer size compounds which facilitate
targeting or delivery of the active ingredient |
GOODS OR SERVICES |
KEEP ALL LISTED |
EXTENSION SECTION |
EXTENSION NUMBER |
2 |
ONGOING EFFORT |
product or service research or development |
ALLOWANCE MAIL DATE |
05/15/2012 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT |
150 |
TOTAL AMOUNT |
150 |
SIGNATURE SECTION |
ORIGINAL PDF FILE |
hw_6547140130-111122298_._LEAN_in_Class_5_-_Signed_Second_Extension_Request__F1222313_.PDF |
CONVERTED PDF FILE(S)
(2 pages) |
\\TICRS\EXPORT16\IMAGEOUT16\854\425\85442528\xml8\ESU0002.JPG |
|
\\TICRS\EXPORT16\IMAGEOUT16\854\425\85442528\xml8\ESU0003.JPG |
SIGNATORY'S NAME |
Jean M. Silveri |
SIGNATORY'S POSITION |
General Counsel |
FILING INFORMATION |
SUBMIT DATE |
Tue May 07 11:16:38 EDT 2013 |
TEAS STAMP |
USPTO/ESU-XX.XX.XXX.XXX-2
0130507111638129156-85442
528-500911f28060bdbd5ac75
5e24a6912de64e28ab9ec8637
cc2b25314a186da-DA-9945-2
0130507111122298114 |
PTO Form 1581 (Rev 9/2005) |
OMB No. 0651-0054 (Exp. 10/31/2017) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: CERULEAN
SERIAL NUMBER: 85442528
The applicant, Cerulean Pharma Inc., having an address of
840 Memorial Drive, 5th Floor
Cambridge, Massachusetts 02139
United States
requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 05/15/2012.
For International Class 005:
Current identification: pharmaceutical preparations for use in the diagnosis, prognosis or prevention of oncological diseases or disorders, including malignant cancers or neoplasms; pharmaceutical
preparations for use in the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including pre-cancerous diseases or disorders and benign cancers or neoplasms,
inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders; pharmaceutical preparations for use in modulating angiogenesis; pharmaceutical preparations for use in
the diagnosis, prognosis and prevention of oncological diseases or disorders, including malignant cancers or neoplasms, all containing nanometer size compounds which facilitate targeting or delivery
of the active ingredient; pharmaceutical preparations for use in the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including pre-cancerous diseases or disorders
and benign cancers or neoplasms, inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders, all containing nanometer size compounds which facilitate targeting or
delivery of the active ingredient; pharmaceutical preparations for use in modulating angiogenesis, containing nanometer size compounds which facilitate targeting or delivery of the active
ingredient
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the second extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension
request: product or service research or development
A fee payment in the amount of $150 will be submitted with the form, representing payment for 1 class.
Declaration
Original PDF file:
hw_6547140130-111122298_._LEAN_in_Class_5_-_Signed_Second_Extension_Request__F1222313_.PDF
Converted PDF file(s) (2 pages)
Signature File1
Signature File2
Signatory's Name: Jean M. Silveri
Signatory's Position: General Counsel
RAM Sale Number: 85442528
RAM Accounting Date: 05/07/2013
Serial Number: 85442528
Internet Transmission Date: Tue May 07 11:16:38 EDT 2013
TEAS Stamp: USPTO/ESU-XX.XX.XXX.XXX-2013050711163812
9156-85442528-500911f28060bdbd5ac755e24a
6912de64e28ab9ec8637cc2b25314a186da-DA-9
945-20130507111122298114